Lupin Ltd. | Balance Sheet

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,076
21,797
11,495
28,674
16,515
Total Accounts Receivable
26,560
28,071
48,805
46,587
56,524
Inventories
21,868
25,613
34,207
37,523
37,511
Other Current Assets
2,501
2,842
4,367
6,745
11,547
Total Current Assets
61,005
78,324
98,874
119,529
122,095
Net Property, Plant & Equipment
29,950
32,454
48,425
56,821
59,211
Total Investments and Advances
360
308
143
232
270
Long-Term Note Receivable
787
897
3
2
49
Intangible Assets
7,716
17,973
70,890
78,147
70,965
Other Assets
1,534
580
4,554
6,264
3,298
Total Assets
102,754
132,272
226,249
266,073
263,054
ST Debt & Current Portion LT Debt
5,028
4,353
18,036
23,183
7,183
Accounts Payable
15,941
19,561
19,888
25,889
25,754
Income Tax Payable
1,127
809
908
980
861
Other Current Liabilities
4,200
12,570
11,779
11,154
17,158
Total Current Liabilities
26,296
37,292
50,612
61,206
50,956
Long-Term Debt
1,510
1,018
53,739
56,478
64,245
Provision for Risks & Charges
1,325
1,620
1,900
3,087
3,569
Deferred Taxes
1,779
1,182
92
1,128
4,310
Other Liabilities
459
441
4,777
6,032
5,258
Total Liabilities
32,768
43,290
114,294
130,752
126,882
Common Equity (Total)
69,307
88,731
111,625
134,967
135,761
Total Shareholders' Equity
69,307
88,731
111,625
134,967
135,761
Total Equity
69,976
88,972
111,945
135,312
136,162
Liabilities & Shareholders' Equity
102,754
132,272
226,249
266,073
263,054
Accumulated Minority Interest
669
241
321
345
401
Non-Equity Reserves
9
9
9
9
9

About Lupin

View Profile
Address
B/4 Laxmi Towers
Mumbai Maharashtra 400051
India
Employees -
Website http://www.lupinworld.com
Updated 09/14/2018
Lupin Ltd. engages in the manufacture of pharmaceutical products. Its offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments.